TITLE

Targeting DNase in cystic fibrosis

AUTHOR(S)
LEDSON, MARTIN J.; WALSHAW, MARTIN J.
PUB. DATE
May 1999
SOURCE
Thorax;May1999, p470
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
66877110

 

Related Articles

  • Thumbs up for DNase.  // Drug Topics;9/6/93, Vol. 137 Issue 17, p64 

    Reports on a Food and Drug Administration advisory panel's recommendation for approval of DNase, Genentech Inc.'s investigational treatment for cystic fibrosis. Pulmozyme as brandname.

  • New drugs for once unyielding diseases. Podolsky, Doug // U.S. News & World Report;5/10/93, Vol. 114 Issue 18, p66 

    Reports on recent developments in the search for cures for Alzheimer's, multiple sclerosis, cystic fibrosis and cerebral palsy. The drug Tacrine for Alzheimer's; Taking Betaseron for multiple sclerosis attacks; Genentech's DNase or Pulmozyme for cystic fibrosis; Brotox, the drug used in...

  • FDA licenses cystic fibrosis treatment.  // FDA Consumer;Mar1994, Vol. 28 Issue 2, p2 

    Comments on the licensing of a product by the Food and Drug Administration (FDA) of the first product in 30 years specifically developed to treat cystic fibrosis. Discussion of Dornase alfa, commonly known as DNase; Incidence of cystic fibrosis in America; Genentech Inc. of San Francisco; Side...

  • Pulmozyme for bronchitis .  // Drug Topics;5/23/94, Vol. 138 Issue 10, p64 

    Reports that DNase, the approved biotechnology drug for cystic fibrosis, improved survival in hospitalized patients with chronic bronchitis. Research at the University of Texas Health Science Center in San Antonio.

  • Promising new therapies in works for cystic fibrosis. Starr, Cynthia // Drug Topics;8/16/93, Vol. 137 Issue 16, p14 

    Discusses development of therapies for cystic fibrosis (CF). Longer life expectancy; Improvement in life quality; CF as leading, fatal inherited disease in the United States; Explanation of disease's mechanism; Use of antibiotics; Basic molecular and genetic defect in CF; Focus on specific...

  • Ireland has the highest rate of cystic fibrosis in the world.  // Daily Mail;1/22/2016, p22 

    WHAT IS CYSTIC FIBROSIS?

  • Two biotech IPOs make debut. Investor's Business Daily // Investors Business Daily;9/19/2014, pA02 

    Cystic fibrosis therapy developer

  • Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis.  // Current Medical Literature: Respiratory Medicine;2003, Vol. 17 Issue 2, p56 

    Discusses the abstract of the article 'Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis,' by R. Suri, R. Grieve, C. Normand et al., published in the Number 57, 2002 issue of the 'Thorax' journal.

  • Pulmonary.  // Africa Health;Jul2011, Vol. 33 Issue 5, p59 

    The article reports on a 5-year follow-up for acute respiratory distress syndrome (ARDS), the large part played by nebulised recombinant human DNase in adults with cystic fibrosis, and the use of inhaled long-acting bronchodilators for patients with severe chronic obstructive pulmonary disease.

  • New drug for cystic fibrosis shows promise.  // Modern Medicine;Feb95, Vol. 63 Issue 2, p56 

    Presents an abstract of the article `Effect of Aerosolized Recombitant Human DNase on Exacerbations of Respiratory Symptoms and on Pulmonary Function in Patients with Cystic Fibrosis by H.J. Fuchs, D.S. Borowitz, et al from the periodical `The New England Journal of Medicine,' dated September 8,...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics